市场调查报告书
商品编码
1384345
免疫球蛋白市场规模(依产品类型(IgG、IgA、IgM)、给药途径(静脉内、皮下)、按应用(原发性免疫缺陷症、继发性免疫缺陷症)、最终用途(医院)和预测),2023 - 2032 年Immunoglobulin Market Size by Product Type (IgG, IgA, IgM), By Route of Administration (Intravenous, Subcutaneous), By Application (Primary Immunodeficiency Disease, Secondary Immunodeficiency Disease) By End-use (Hospitals) & Forecast, 2023 - 2032 |
由于免疫缺陷疾病(包括原发性免疫缺陷疾病和继发性免疫缺陷疾病)发生率不断上升,免疫球蛋白市场规模预计在2023年和2032年期间CAGR将达7.7%。根据美国国家医学图书馆 2021 年的报告,全球有超过 600 万人受到原发性免疫缺陷的影响,其中近 70% 至 90% 未被诊断出来。
免疫球蛋白在治疗各种自体免疫疾病和发炎性疾病的广泛应用正在促进市场成长。正在进行的生物技术研发活动进一步促进了创新免疫球蛋白产品的推出,培育了竞争激烈的市场格局。
整个免疫球蛋白产业根据产品类型、给药途径、应用、最终用途和地区进行分类。
到 2032 年,IgA 产品类型细分市场将获得巨额收入,因为免疫球蛋白 A (IgA) 是免疫系统的关键组成部分,可提供针对感染的基本防御。 IgA可有效预防呼吸道和胃肠道等黏膜组织的感染。随着研究的进展,基于 IgA 的疗法将成为治疗各种疾病的有前景的途径,进一步巩固该领域的重要性。
预计到2032 年,多灶性运动神经病变(MMN) 领域将出现大幅增长。MMN 是一种以肌肉无力和萎缩为特征的罕见神经系统疾病,其患病率不断上升,正在推动对免疫球蛋白治疗的需求。随着临床试验和研究工作不断探索免疫球蛋白在管理 MMN 症状方面的功效,这个应用领域有望成为一个利润丰厚的市场途径。
由于医疗保健支出增加、免疫缺陷疾病盛行率上升以及人口老化,预计亚太地区免疫球蛋白市场从 2023 年到 2032 年将录得强劲的CAGR。此外,整个地区医疗基础设施的进步以及人们对免疫球蛋白疗法益处的认识不断提高,正在塑造亚太地区的产业动态。
Immunoglobulin market size is predicted to observe 7.7% CAGR during 2023 and 2032 owing to the escalating incidence of immunodeficiency disorders, including primary immunodeficiency diseases and secondary immunodeficiency diseases. According to a 2021 report by National Library of Medicine, more than 6 million people across the globe are affected by primary immunodeficiencies, of which nearly 70% to 90% are not diagnosed.
The expanding applications of immunoglobulin in treating various autoimmune and inflammatory diseases is bolstering market growth. The ongoing R&D activities in biotechnology are further contributing to the introduction of innovative immunoglobulin products, fostering a competitive market landscape.
The overall immunoglobulin industry is classified based on product type, route of administration, application, end-use, and region.
The IgA product type segment will garner massive revenues by 2032 as immunoglobulin A (IgA) is a key component of the immune system which provides essential defense against infections. IgA is effective in preventing infections in mucosal tissues such as the respiratory and gastrointestinal tracts. As research advances, IgA-based therapies will emerge as a promising avenue in the treatment of various diseases, further solidifying the significance of this segment.
The multifocal motor neuropathy (MMN) segment is anticipated to witness substantial growth through 2032. The rising prevalence of MMN, a rare neurological disorder characterized by muscle weakness and atrophy, is fueling the demand for immunoglobulin therapies. With ongoing clinical trials and research endeavors exploring the efficacy of immunoglobulins in managing MMN symptoms, this application segment is poised to be a lucrative avenue for the market.
Asia Pacific immunoglobulin market is expected to record strong CAGR from 2023 to 2032 owing to the increasing healthcare expenditure, rising prevalence of immunodeficiency disorders, and a growing aging population. Moreover, advancements in the healthcare infrastructure across the region and a surge in awareness regarding the benefits of immunoglobulin therapies are shaping the Asia Pacific industry dynamics.